bortezomib,lenalidomide,dexamethasone,daratumumab
janssen,takeda
final analysis of ph 2 griffin study by douglas sborov. dara-rvd with dara-r maint. vs rvd with r maint. in nd transplant eligible (te) #myeloma. d-rvd superior in mrd negativity, pfs, and data may support this quad therapy with doublet maint. as new soc in te ndmm. #ims2022 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.